Trial Profile
PHASE 1B OPEN-LABEL STUDY OF THE SAFETY AND CLINICAL ACTIVITY OF CRIZOTINIB (PF-02341066) IN TUMORS WITH GENETIC EVENTS INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK ) GENE LOCUS
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 15 Nov 2023
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Muscle tissue neoplasms; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 07 Nov 2023 Status changed from active, no longer recruiting to discontinued.
- 21 Aug 2023 Planned End Date changed from 31 Jul 2023 to 7 Sep 2023.
- 21 Aug 2023 Planned primary completion date changed from 31 Jul 2023 to 7 Sep 2023.